Cargando…

Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials

BACKGROUND: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy (ET) deeply transformed the treatment landscape of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer. Randomized clinical trials suggest that second progress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Munzone, E., Pagan, E., Bagnardi, V., Montagna, E., Cancello, G., Dellapasqua, S., Iorfida, M., Mazza, M., Colleoni, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645913/ https://www.ncbi.nlm.nih.gov/pubmed/34864350 http://dx.doi.org/10.1016/j.esmoop.2021.100332

Ejemplares similares

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida, Monica, et al.
Publicado: (2020)

Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
por: Montagna, Emilia, et al.
Publicado: (2020)

Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines
por: Munzone, Elisabetta, et al.
Publicado: (2019)

Management of breast cancer patients during the peak of the COVID 19 pandemic
por: Montagna, E., et al.
Publicado: (2021)

Pegylated Liposomal Doxorubicin (Caelyx(®)) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial
por: Dellapasqua, Silvia, et al.
Publicado: (2021)

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
por: Torrisi, R, et al.
Publicado: (2007)

Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
por: Montagna, Emilia, et al.
Publicado: (2019)

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)

Reply to Comments on: “Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp cooling system in early breast cancer patients treated with anthracyclines.”
por: Munzone, Elisabetta, et al.
Publicado: (2019)

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?
por: Van Baelen, Karen, et al.
Publicado: (2023)

Optimal management of luminal breast cancer: how much endocrine therapy is long enough?
por: Munzone, Elisabetta, et al.
Publicado: (2018)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21
por: Colleoni, B, et al.
Publicado: (2017)

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
por: Torrisi, R, et al.
Publicado: (2008)

Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers
por: Tang, Hiu, et al.
Publicado: (2023)

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer
por: Knudsen, Erik S., et al.
Publicado: (2016)

Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
por: Cancello, Giuseppe, et al.
Publicado: (2008)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor()
por: Beije, Nick, et al.
Publicado: (2016)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
por: Zhao, Joseph J., et al.
Publicado: (2023)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point
por: Bisteau, Xavier, et al.
Publicado: (2013)

Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis
por: Bianco, Nadia, et al.
Publicado: (2021)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression
por: Yanai, Yoshinori, et al.
Publicado: (2020)

Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States
por: Zanotti, Giovanni, et al.
Publicado: (2017)

CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer
por: Filippone, M. G., et al.
Publicado: (2022)

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
por: Lindeman, Geoffrey J., et al.
Publicado: (2022)

Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer
por: Montagna, E, et al.
Publicado: (2008)

CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
por: Behrouzi, Roya, et al.
Publicado: (2023)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
por: Orlando, Laura, et al.
Publicado: (2006)

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
por: Grinshpun, Albert, et al.
Publicado: (2023)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
por: Kaminska, Kamila, et al.
Publicado: (2021)

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
por: Karimi, Leena, et al.
Publicado: (2023)

Apigenin Inhibits Growth of Breast Cancer Cells: The Role of ERα and HER2/neu
por: Scherbakov, A. M., et al.
Publicado: (2015)

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
por: Ferrando, Lorenzo, et al.
Publicado: (2023)

Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
por: Al-Qasem, Abeer J., et al.
Publicado: (2021)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dfe3np1s22rq3p72qgdtccvho8